Low-Carb And Low-Fat Diets Battle To A Draw

A new study comparing a low-carbohydrate diet with a low-fat diet found no important differences in weight loss or other important outcomes between the two diets. Some experts believe the result shows that the  debate over the relative worth of these different diets has been overblown and confirms the view that calories count. Others say…

Click here to continue reading…

Moment Of Truth For Struggling And Expensive Cholesterol Drugs

It will be the moment of truth for the expensive new cholesterol drugs known as PCSK9 inhibitors. Next month we will learn much more about the PCSK9 inhibitor class of cholesterol drugs. A lot of the remaining uncertainty about the efficacy— or lack of efficacy— of these drugs will be resolved when a large cardiovascular…

Click here to continue reading…

The Hypertension Guideline War Is Not A Fake War

The war over the new blood pressure guideline is not a fake war or a childish dispute. It is a real war over genuine differences in how we should think about health and disease and prevention. The publication last November of the new US blood pressure guideline sparked a vigorous and important debate. A central part…

Click here to continue reading…

Statin Critic Accused Of Image Manipulation In Earlier Research

A journalist who has been a frequent critic of statins has been publicly accused of scientific misconduct involving image manipulation in an earlier research paper. Maryanne Demasi is an Australian journalist who has a PhD in Rheumatology from the Royal Adelaide Hospital in South Australia. She has been a frequent critic of statins, a proponent of…

Click here to continue reading…

More Mini-Trials And Fewer Mega-Trials?

Just as dinosaurs ruled the earth for millions of years, for more than 30 years now cardiology has been ruled by mega-trials. Over the years the cardiology landscape would shake and tremble as ever more gigantic mega-trials emerged to  dominate the field. Just as the giant dinosaurs paid no attention to the seemingly inconsequential little…

Click here to continue reading…

Nuance And The Healthcare Apocalypse

(Updated) If you actually have a life you may not be aware that there’s been a fierce debate on Twitter and the blogosphere over Lisa Rosenbaum’s NEJM article decrying the oversimplification and self-righteousness of the “less is more crusade.”  In response to fierce criticism, from myself, the Lown Institute, and others, Saurabh Jha praised and defended Rosenbaum for embracing nuance…

Click here to continue reading…

Ms. Inappropriate Defends The Status Quo

I think I would have liked the younger Lisa Rosenbaum, the cardiologist who last week in the New England Journal of Medicine launched a missile at the “less is more” movement. Here’s how her piece begins: They called me Ms. Appropriate. When I was a cardiology fellow, health care costs were skyrocketing, and I considered devoting…

Click here to continue reading…

Will ORBITA Change Clinical Practice? The Role of Perverse Economic Incentives

Editor’s note: In this guest post Sanjay Kaul (Cedars-Sinai) explains why it is unlikely that the ORBITA trial will have a big impact on clinical practice. Guest Post: Will ORBITA Change Clinical Practice? The Role of Perverse Economic Incentives.   by Sanjay Kaul, MD (Cedars-Sinai Medical Center) Shortly after celebrating the 40th anniversary of PCI, first…

Click here to continue reading…

In Defense Of ORBITA

–The trial investigators respond to their numerous critics. If you’ve been reading about ORBITA then you probably know that the first ever placebo-controlled trial of PCI was interesting and provocative. But you’ve also probably heard that the trial was too small, too short and performed in patients who should not have been studied. Simultaneously, you…

Click here to continue reading…

Clinical Trials: You Can’t Always Get What You Want

–Trial investigators have lost control of their trials’ messages. Editor’s Note: The following is a lightly edited version of a talk I presented (without slides!) at the CVCT workshop in Washington, DC earlier this week. The topic was the changing role of media in communicating the results of clinical trials. When it comes to the…

Click here to continue reading…

After Slow Start Entresto Is Poised For Takeoff

–Novartis sees open road to blockbuster status for heart failure drug After a slow start, the novel heart failure drug Entresto (valsartan/sacubitril) is now poised to become a blockbuster, if drugmaker Novartis’s projections are on target. The combination pill will record sales of about $500 million in 2017 and may eventually achieve $5 billion in…

Click here to continue reading…

Why was ORBITA MIA at the AHA?

By offering a last minute 2-for-1 deal shortly before its annual meeting in Anaheim the American Heart Association signalled its desperation. During the meeting, as the tumbleweed rolled down the lonely halls of the Anaheim Convention Center, the reason for the deal was apparent to everyone. The lack of crowds, the low energy, the paucity…

Click here to continue reading…

The Survey Says: BP Measurement In SPRINT Was All Over The Place

–BP measurement question limits the trial’s ability to inform clinical practice. A long-promised report from the SPRINT investigators offers important new information about how blood pressure was monitored in the trial. The report is unlikely to satisfy critics or resolve the larger controversy of how the trial should be interpreted. At the American Heart Association…

Click here to continue reading…

AHA President Suffers A Heart Attack Monday Morning

–The AHA reports that he received a stent and is doing well. The president of the American Heart Association, John Warner, had a “mild heart attack” on Monday morning, according to the AHA. Warner received a stent at an undisclosed hospital. The AHA said he is “doing well.” Warner is 52. The attack occurred while…

Click here to continue reading…

New Blood Pressure Guideline Sets Lower 130/80 Threshold

Expanded guideline means more than 100 million people have high blood pressure. The new US blood pressure guideline lowers the definition of high blood pressure to 130/80 mm Hg. This means that more than 100 million adults will now have high blood pressure, though many will be unaware of the diagnosis. The 192 page guideline…

Click here to continue reading…

CANTOS Substudy Shows Major Role For Inflammation

–Large reductions in hsCRP appeared to foretell improved outcomes. ANAHEIM — An important CANTOS trial substudy bolsters evidence that inflammation plays an independent role in cardiovascular disease (CVD) and may point toward a new targeted approach to treatment of CVD and perhaps even more profoundly impact cancer treatment. The report, presented by Paul Ridker (Brigham…

Click here to continue reading…

ORBITA Trial Puts Interventional Cardiologists On The Defensive

(Updated) Since it’s debut a week ago the ORBITA trial has provoked the most furious debate in cardiology since the COURAGE trial a decade earlier. But the ORBITA debate has proceeded far faster, fuelled by Twitter and its ability to  instantaneously deliver point and counterpoint. Although ORBITA has been showered with praise for its innovative…

Click here to continue reading…

The Story Behind The NY Times ORBITA Anecdote

–Brahmajee Nallamothu fills in the details about the patient who didn’t get a stent because of ORBITA. Editor’s note: The New York Times story by Gina Kolata on the ORBITA trial focused on one patient who decided not to have a stent implanted when he heard about the ORBITA trial. Here is a more complete…

Click here to continue reading…

Diving Deep Into The ORBITA Trial

William Boden, Ajay Kirtane, and Dan Mark analyze the ORBITA trial. Editor’s note: I asked a wide variety of cardiologists for their thoughts about ORBITA, presented at the TCT meeting in Denver and published simultaneously in the Lancet. Three of them, William Boden, Ajay Kirtane, and Dan Mark, sent highly detailed comments about the trial….

Click here to continue reading…

Small Trial Raises Big Concerns That PCI In Stable Angina Is Just A Placebo

ORBITA trial may spark a heated debate in the cardiology community. It is only a small trial but it may have an enormous impact as it raises major questions about one of the core beliefs of clinical cardiology as it suggests that PCI for stable coronary disease has no more effect than a sham procedure….

Click here to continue reading…

Guest Post: Future Cardiologists Lack Vision

Editor’s note: Ethan Weiss, MD, is a cardiologist at the University of California at San Francisco. He recently tweeted his thoughts after interviewing applicants for his hospital’s cardiology fellowship. Here is a lightly edited version of his thread. Just finished cardiology fellowship interviews for the season – a few thoughts: Career path: Still fewer applicants…

Click here to continue reading…

Why Do Doctors Still Rely On LDL Instead Of Non-HDL Cholesterol?

–There’s broad agreement that non-HDL is a better measure than LDL. For decades lipid experts have been saying that non-HDL is preferable to LDL cholesterol in the assessment of cardiovascular risk. The subject is not controversial. Although they may disagree about its precise significance, every expert I contacted agreed that non-HDL is superior to LDL….

Click here to continue reading…

Merck Drops Development Of Once Promising CETP Inhibitor

–Despite positive results in the REVEAL trial anacetrapib is dead. Merck announced on Wednesday that it would not seek regulatory approval for its cholesterol drug anacetrapib. The decision did not surprise most observers, despite the fact that investigators recently reported positive results for the drug in the enormous 30,000+ patient REVEAL trial. The trial was…

Click here to continue reading…

Side Effects In Drug Ads Don’t Add Up

–The long recitation of all possible side effects dilutes the perception of risk. One of the most perplexing aspects of the ubiquitous direct to consumer (DTC) prescription drug advertisements is the seemingly endless recitation of side effects in drug ads. The list is, alternatively, horrifying, boring, concerning, and silly. It is reasonable to wonder how these…

Click here to continue reading…

Upcoming US Guideline Will Likely Set 130/80 As New Blood Pressure Target

–The highly anticipated AHA/ACC BP guideline will be published in November. The new magic number will be 130 over 80 mm Hg. That’s the new blood pressure goal that many hypertension experts say will be the centerpiece of the new US blood pressure guidelines. The new guideline will be introduced next month in Anaheim during the…

Click here to continue reading…